Article
Oncology
Yunshi Cai, Kunlin Xie, Mohammad Natheir Adeeb Alhmoud, Tian Lan, Haifeng Wan, Die Hu, Ling Lan, Chang Liu, Hong Wu
Summary: This study evaluated the diagnostic and prognostic values of Prothrombin induced by vitamin K absence-II (PIVKA-II) and Alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC), and investigated their clinical utility in patient selection for different surgical approaches. The results showed that both PIVKA-II and AFP were independent prognostic markers, and their combined status performed better in predicting overall survival (OS) and recurrence-free survival (RFS) of HCC patients compared to using PIVKA-II or AFP alone. Extra caution is needed when applying the laparoscopic approach in HCC patients with PIVKA-II (+) and AFP (+) status.
Article
Medical Laboratory Technology
Shan Tian, Yongyi Chen, Yimin Zhang, Xiaohong Xu
Summary: The accuracy of AFP as a diagnostic marker for HCC is insufficient, and the application of PIVKA-II in HCC is still controversial. Combined detection of AFP and PIVKA-II is superior to both tests alone. The level of PIVKA-II is correlated with the severity and prognosis of HCC, while the level of AFP is not.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2023)
Review
Biochemistry & Molecular Biology
Libin Dong, Xun Qiu, Fengqiang Gao, Kai Wang, Xiao Xu
Summary: PIVKA-II plays an important role in HCC and can serve as a biomarker for screening, diagnosis, prediction, and treatment. Joint detection of PIVKA-II and other biomarkers can improve diagnostic accuracy, and PIVKA-II is also an indicator for prognosis prediction, transplantation eligibility, and vitamin K status.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)
Article
Veterinary Sciences
Lorella Maniscalco, Katia Varello, Emanuela Morello, Vittoria Montemurro, Matteo Olimpo, Davide Giacobino, Giuseppina Abbamonte, Cecilia Gola, Selina Iussich, Elena Bozzetta
Summary: PIVKA-II expression in canine hepatocellular carcinoma cannot be considered as a marker of malignancy or a prognostic marker, as prognosis usually depends on clinical presentation. Currently, prognostic parameters in canine hepatocellular carcinoma that can predict aggressive behavior through histological examination are still lacking.
VETERINARY SCIENCES
(2022)
Article
Multidisciplinary Sciences
Tianying Ren, Xu Hou, Xin Zhang, Dongliang Chen, Juan Li, Yingnan Zhu, Zhiheng Liu, Dawei Yang
Summary: In this study, we developed the AALP model to differentiate between HCC and CLD patients based on serum biomarkers. The AALP model showed good sensitivity and specificity for HCC detection, and also performed well in the subgroup of CLD patients. Furthermore, we demonstrated the consistency between AFP-L3 and PIVKA II levels and imaging results.
Article
Medicine, General & Internal
Shu An, Xiaoxia Zhan, Min Liu, Laisheng Li, Jian Wu
Summary: The study aimed to develop a better diagnostic and prognostic model for HBV-associated HCC by combining AFP with PIVKA-II and other potential serum/plasma protein biomarkers. A total of 578 patients were enrolled, and AFP and PIVKA-II levels were found to be significantly increased in HBV-related HCC. The diagnostic and prognostic nomograms based on these biomarkers showed high efficacy in discriminating HCC from liver cirrhosis and chronic HBV, as well as predicting survival.
Article
Oncology
Honglei Feng, Bole Li, Ze Li, Qian Wei, Li Ren
Summary: The study found that PIVKA-II is a promising biomarker for HCC diagnosis, with remarkable diagnostic performance as an individual biomarker, and its combination with AFP can significantly improve the diagnostic efficiency of HCC. There were significant correlations between PIVKA-II expression levels and certain clinicopathological characteristics, and PIVKA-II can be used to evaluate the curative effects of surgical treatment for HCC.
Article
Oncology
Shinji Unome, Kenji Imai, Koji Takai, Takao Miwa, Tatsunori Hanai, Yoichi Nishigaki, Hideki Hayashi, Takahiro Kochi, Shogo Shimizu, Junji Nagano, Soichi Iritani, Atsushi Suetsugu, Masahito Shimizu
Summary: This study evaluated the efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma and analyzed the factors affecting overall survival. The results showed promising therapeutic effects and identified specific clinical indicators that correlated with patient survival.
Article
Agriculture, Dairy & Animal Science
Lorella Maniscalco, Katia Varello, Simona Zoppi, Giuseppina Abbamonte, Marta Ferrero, Elena Torres, Federica Ostorero, Francesca Rossi, Elena Bozzetta
Summary: PIVKA-II is an aberrant form of vitamin K used to detect human coagulation disorders and some neoplastic diseases, as well as to distinguish anticoagulant poisoning from other coagulopathies. The immunohistochemical expression of PIVKA-II can effectively identify patients with coagulation disorders.
Article
Public, Environmental & Occupational Health
Youran Chen, Yanyan Yang, Shanshan Li, Minghao Lin, Xueting Xie, Huifang Shi, Yuchun Jiang, Sijie Zheng, Hui Shao, Naibin Yang, Mingqin Lu
Summary: The study aimed to investigate the role of PIVKA-II in hepatitis E and its clinical significance. It was found that increased PIVKA-II levels were associated with hepatic insufficiency in patients with hepatitis E. The levels of PIVKA-II were transiently increased and correlated with the disease course.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Medicine, General & Internal
Tyng-Yuan Jang, Chia-Yen Dai
Summary: This study aimed to investigate the diagnostic value of PIVKA-II levels in patients with suspected HCC and found that combining PIVKA-II with AFP can improve diagnostic performance.
Article
Medicine, General & Internal
Li Huan
Summary: This study investigated the efficacy of combined detection of 5 serological tumor markers in the early diagnosis of primary liver cancer. The results showed that serum MIF, GP73, PIVKA-II, AFP-L3, and AFP all have certain diagnostic value for primary liver cancer, and the combined detection of these markers significantly improved the sensitivity, specificity, and accuracy of the diagnosis, providing higher diagnostic value.
PAKISTAN JOURNAL OF MEDICAL SCIENCES
(2021)
Article
Oncology
Xuqi Sun, Jie Mei, Wenping Lin, Ziliang Yang, Wei Peng, Jinbin Chen, Yaojun Zhang, Li Xu, Minshan Chen
Summary: This study demonstrated that early reductions in AFP and PIVKA-II can serve as predictors of the efficacy of PD-1 blockade in hepatocellular carcinoma patients. The study found a positive correlation between AFP and PIVKA-II reductions > 50% and better outcomes in terms of objective response rate, progression-free survival, and overall survival.
Review
Medicine, General & Internal
Mirela Georgiana Perne, Adela-Viviana Sitar-Taut, Teodora Gabriela Alexescu, Lorena Ciumarnean, Mircea-Vasile Milaciu, Sorina-Cezara Coste, Calin-Vasile Vlad, Angela Cozma, Dan-Andrei Sitar-Taut, Olga Hilda Orasan, Alexandra Craciun
Summary: The early diagnosis of hepatocellular carcinoma (HCC) can benefit from the use of alpha-fetoprotein (AFP) and imaging diagnosis. However, some cases are missed or diagnosed late. Therefore, new tools, such as serum markers and imaging techniques, are being reconsidered. In this study, the diagnostic performance of protein induced by vitamin K absence or antagonist II (PIVKA II) compared to AFP was investigated. The results showed that PIVKA II had better diagnostic accuracy for HCC compared to AFP, suggesting its potential usefulness in combination with AFP and ultrasound examination.
Article
Chemistry, Analytical
Lorico D. S. Lapitan Jr, Mariusz Pietrzak, Marek Krawczyk, Elzbieta Malinowska
Summary: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally in 2020. The complexity of the disease and the low survival rate are due to late-stage diagnosis. Therefore, developing simple, sensitive, and rapid screening methods for early detection is necessary. Recent studies have shown promising HCC biomarkers and ultrasensitive biosensor technologies that could significantly improve diagnosis.
SENSORS AND ACTUATORS B-CHEMICAL
(2023)
Article
Gastroenterology & Hepatology
Abdelfattah M. Attallah, Mohamed El-Far, Camelia A. Abdel Malak, Mohamed M. Omran, Khaled Farid, Raida S. Yahya, Entsar A. Saad, Mohamed S. Albannan, Ahmed A. Attallah, Mohamed A. El. Basuni, Islam S. Ali, Safaa B. Abed, Mohamed A. El Naggar
ANNALS OF HEPATOLOGY
(2015)
Article
Oncology
Camelia Abdel-Malak, Hossam Darwish, Afaf Elsaid, Fatma El-Tarapely, Rami Elshazli
Article
Oncology
Afaf Elsaid, Rami Elshazli, Fatma El-Tarapely, Hossam Darwish, Camelia Abdel-Malak
Article
Cell & Tissue Engineering
Sherif Khodeer, Takumi Era
Article
Medical Laboratory Technology
Abdelfattah M. Attallah, Mohamed El-Far, Camelia A. Abdel Malak, Faten Zahran, Khaled Farid, Mohamed M. Omran, Hayat Zagloul, Mohamed S. El-Deen
CLINICA CHIMICA ACTA
(2011)
Article
Medical Laboratory Technology
C. A. Abdelmalak, R. S. Yahya, D. M. Elghannam, A. E. El-Khadragy, H. M. Abd El Messih
CLINICAL LABORATORY
(2014)
Article
Biochemistry & Molecular Biology
Heba A. Aniss, Ashraf El Metwally Said, Ibrahim H. El Sayed, Camelia Adly
Article
Cell Biology
Sherif Khodeer, Arne Klungland, John Arne Dahl
Summary: This study reveals that the RNA-specific N6-methyladenosine (m(6)A) demethylase ALKBH5 plays a critical role in somatic cell reprogramming through its catalytic activity. Knockdown or knockout of Alkbh5 reduces reprogramming efficiency by inhibiting cell proliferation and decreasing the upregulation of epithelial markers. Overexpression of ALKBH5 at the late reprogramming phase enhances reprogramming by stabilizing Nanog transcripts and increasing Nanog expression.
JOURNAL OF CELL SCIENCE
(2022)
Article
Cell & Tissue Engineering
Thi Xuan Ai Pham, Amitesh Panda, Harunobu Kagawa, San Kit To, Cankat Ertekin, Grigorios Georgolopoulos, Sam S. F. A. van Knippenberg, Ryan Nicolaas Allsop, Alexandre Bruneau, Jonathan Sai-Hong Chui, Lotte Vanheer, Adrian Janiszewski, Joel Chappell, Michael Oberhuemer, Raissa Songwa Tchinda, Irene Talon, Sherif Khodeer, Janet Rossant, Frederic Lluis, Laurent David, Nicolas Rivron, Bradley Philip Balaton, Vincent Pasque
Summary: The specification and development of extraembryonic mesoderm (EXM) during primate postimplantation embryogenesis occurs before gastrulation, in contrast to rodents. This study demonstrates that naive human pluripotent stem cells (hPSCs) have the ability to differentiate into EXM cells (EXMCs). EXMCs are specified by inhibiting Nodal signaling and GSK3B, and their maintenance relies on mTOR and BMP4 signaling activity. The transcriptome and epigenome of EXMCs closely resemble that of human and monkey embryo EXM, indicating their similarity to in vivo counterparts. This finding has significant implications for modeling and studying early human embryogenesis and related defects.
Article
Oncology
Mohamed A. Abdel-Mohsen, Camelia A. Abdel Malak, Morsy A. Abou Yossef, Eman S. El-Shafey
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2017)
Article
Medical Laboratory Technology
AM Attallah, CAA Malak, NA Elghawalby, AS Shehatta, M Abdel-Raouf, GE Shiha
CLINICA CHIMICA ACTA
(2004)
Article
Biochemical Research Methods
AM Attallah, CAA Malak, H Ismail, AH El-Saggan, MM Omran, AA Tabll
JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY
(2003)